Bladder Cancer, Loss of Y Chromosome, and New Opportunities for Immunotherapy Arun K. MankanNagender MankanKamal S. Saini Commentary 10 January 2024 Pages: 885 - 890
Autologous Skin Cell Suspension for Full-Thickness Skin Defect Reconstruction: Current Evidence and Health Economic Expectations Steven A. KahnJeffrey E. CarterJeremiah A. Sparks Commentary Open access 22 January 2024 Pages: 891 - 900
Can the Evidence-Based Use of Probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) Mitigate the Clinical Effects of Antibiotic-Associated Dysbiosis? Dan WaitzbergFrancisco GuarnerHarry Sokol Commentary Open access 30 January 2024 Pages: 901 - 914
The Evolving Role of PD-(L)1 Inhibition in Optimizing Outcomes for High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): A Podcast Peter C. BlackBernhard J. Eigl Commentary Open access 02 February 2024 Pages: 915 - 927
Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b Study Emma Guttman-YasskyEric L. SimpsonMasutaka Furue Summary of Research Open access 08 January 2024 Pages: 928 - 931
Comparative Safety of Pulsed Field Ablation and Cryoballoon Ablation Technologies for Pulmonary Vein Isolation in Patients with Paroxysmal Atrial Fibrillation: A Critical Literature Review and Indirect Treatment Comparison Sonia MaccioniReecha SharmaJohan Vijgen Review Open access 08 January 2024 Pages: 932 - 944
The Cost of Seasonal Influenza: A Systematic Literature Review on the Humanistic and Economic Burden of Influenza in Older (≥ 65 Years Old) Adults Jakob LangerVerna L. WelchIsabelle Whittle Review Open access 23 January 2024 Pages: 945 - 966
Artificial Intelligence in Liver Diseases: Recent Advances Feifei LuYao MengXingshun Qi Review 29 January 2024 Pages: 967 - 990
A Randomized, Open-Label Study Conducted to Evaluate the Bioequivalence of Pegfilgrastim-cbqv On-Body Injector Versus Prefilled Syringe in Healthy Male Participants Hong TangFrancesca CivoliBarbara Finck Original Research Open access 05 January 2024 Pages: 991 - 1009
Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing Laurent KodjikianLluís Arias BarquetSergio Leal Original Research Open access 06 January 2024 Pages: 1010 - 1024
Co-crystal of Tramadol-Celecoxib Versus Tramadol or Placebo for Acute Moderate-to-Severe Pain After Oral Surgery: Randomized, Double-Blind, Phase 3 Trial (STARDOM1) Richard LangfordEsther M. Pogatzki-ZahnCarlos Plata-Salamán Original Research Open access 06 January 2024 Pages: 1025 - 1045
Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis Amy S. PallerAndreas PinterMike Bastian Original Research Open access 09 January 2024 Pages: 1046 - 1061
Ralinepag Phase II Open-Label Extension Study in Patients with Pulmonary Arterial Hypertension Joan BarberàPavel JansaNamita Sood Original Research Open access 10 January 2024 Pages: 1062 - 1074
Assessing the Burden and Cost of COVID-19 Across Variants in Commercially Insured Immunocompromised Populations in the United States: Updated Results and Trends from the Ongoing EPOCH-US Study Amita KetkarVincent WilleyMonica Verduzco-Gutierrez Original Research Open access 13 January 2024 Pages: 1075 - 1102
Real-World Management of Patients with Pulmonary Arterial Hypertension: Insights from EXPOSURE Audrey MullerPilar Escribano-SubiasSean Gaine Original Research Open access 13 January 2024 Pages: 1103 - 1119
Burden of Illness of Type 2 Diabetes Mellitus in the Kingdom of Saudi Arabia: A Five-Year Longitudinal Study Mohammed AlHarbiAbdullah OthmanZein AlGhamdi Original Research Open access 19 January 2024 Pages: 1120 - 1150
Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan Navdeep TangriAnjay RastogiTadashi Sofue Original Research Open access 19 January 2024 Pages: 1151 - 1167
Roxadustat and Oral Iron Absorption in Chinese Patients with Anemia of Chronic Kidney Disease: A Randomized, Open-Label, Phase 4 Study (ALTAI) Haiting WuHong ChengXuemei Li Original Research Open access 27 January 2024 Pages: 1168 - 1183
Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study Michael LehrkeAnja VogtKausik K. Ray Original Research Open access 30 January 2024 Pages: 1184 - 1200
Effect of Individual Patient Characteristics and Treatment Choices on Reliever Medication Use in Moderate-Severe Asthma: A Poisson Analysis of Randomised Clinical Trials Sven C. van DijkmanArzu YorgancıoğluOscar Della Pasqua Original Research Open access 01 February 2024 Pages: 1201 - 1225
Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis Andrew IpAlex MutebiBrian Elliott Original Research Open access 02 February 2024 Pages: 1226 - 1244
Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Meredith McCormackRosirene PaczkowskiReynold Panettieri Original Research Open access 04 February 2024 Pages: 1245 - 1261
The Association Between Short-Acting β2-Agonist Over-Prescription, and Patient-Reported Acquisition and Use on Asthma Control and Exacerbations: Data from Australia David PriceChristine Jenkinsthe OPCA Improving Asthma Outcomes in Australia Research Group Original Research Open access 04 February 2024 Pages: 1262 - 1283
Efficacy and Safety of Esaxerenone in Hypertensive Patients with Left Ventricular Hypertrophy (ESES-LVH) Study: A Multicenter, Open-Label, Prospective, Interventional Study Eiichiro YamamotoHiroki Usukuthe ESES-LVH investigators Original Research Open access 04 February 2024 Pages: 1284 - 1303
